DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

NCT06075953 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Ductal Carcinoma in Situ

Interventions

DRUG: Tamoxifen
DRUG: Exemestane
DRUG: Letrozole
DRUG: Anastrazole
DRUG: Testosterone + Anastrazole
DRUG: Elacestrant
DRUG: Z-endoxifen

Sponsor

QuantumLeap Healthcare Collaborative